Daniel Wilkinson Profile
Daniel Wilkinson

@DSWilkinsonPhD

Followers
35
Following
64
Media
0
Statuses
5

Postdoc in the Fecci Lab by day…and also by night. Developing novel T cell-based therapeutics for GBM as a part of the Duke Brain Tumor Immunotherapy Program.

Joined May 2022
Don't wanna be here? Send us removal request.
@DSWilkinsonPhD
Daniel Wilkinson
2 years
Honored and excited to have work from our group and led by @EmilyCLerner included in this collection!
@NatureCancer
Nature Cancer
2 years
✨In our #2023InReview special we provide a collection of 12 research highlights summarizing impactful papers published in 2023 and present a collection of some of our most striking @NatureCancer publications. Check them out for some end-of-year reading. https://t.co/6uhjoH90kG
0
0
4
@ImmunoPodcast
Immunology Podcast
2 years
📣 Check out our latest episode! Dr. @PeterFecci from @DukeMets talks about activating #Tcells to target brain tumors and his team’s work on targeting MHC-I-negative tumor cells. Listen now: https://t.co/XmO4BowUkh
0
2
7
@DSWilkinsonPhD
Daniel Wilkinson
2 years
Really interesting and exciting stuff!
@ACIR_org
ACIR
2 years
Lerner and Woroniecka et al. showed that CD8+ T cell-dependent immunotherapies remain effective against β2m-lacking tumor cells, independent of NK cells, via CD8+ T cell-mediated cytotoxicity [...] https://t.co/XKov0jYJcL  @EmilyCLerner  @DukeMedSchool
0
1
2
@BryanDChoi
Bryan D. Choi MD PhD
3 years
Extraordinary clinical responses to CAR T cell therapy for solid tumors (heavily pretreated neuroblastoma) published in @NEJM from investigators in Italy! https://t.co/KqZKLx6LVp
Tweet card summary image
nejm.org
Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for patients with high-risk neurobl...
2
9
35
@NatRevImmunol
Nature Rev Immunol
3 years
Adaptive meets innate: CD8+ T cells kill MHC-I-negative tumour cells
3
32
89